Novartis AG (ADR) (N:NVS)
Business Focus: Pharmaceuticals
Apr 15, 2024 02:00 pm ET
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide2; complement activation is a key driver of glomerular inflammation in IgAN3,4There is a need for effective, targeted therapies for IgAN2,5; up to 30% of patients with persistent proteinuria (≥1 g/day) may progress to kidney failure within 10 years, requiring maintenance dialysis and/or kidney transplantation6Novartis continues
Apr 11, 2024 07:00 am ET
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treat
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis (NYSE: NVS) for the...
Apr 06, 2024 04:16 pm ET
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm while maintaining adherence to statin treatment1Results from usual care arm reinforce the urgent need for more aggressive LDL-C lowering in ASCVD patients, 92% of whom did not reach t
Feb 14, 2024 08:00 am ET
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced two clinical trial...
Dec 10, 2023 06:39 pm ET
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigue in the majority of patients, with a safety profile consistent with previously reported data1-5Patients switching from anti-C5s to Fabhalta in the extension period achieved outcomes comparable to the Fabhalta arm in the 24-week randomized controlled period, including transfusion avoidance and near-normal hemoglobin-levels (
Dec 05, 2023 11:18 pm ET
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients1-5 In APPLY-PNH, patients who switched to Fabhalta experienced superior increases of hemoglobin levels ≥ 2 g/dL (82.3% vs. 0%) and hemoglobin level ≥ 12 g/dL (67.7% vs. 0%), both in the absence of red blood cell transfusions, vs. patients who continued on anti-C5 treatment1,2 Fabhalta, now available for both previously treated and treatment-naïve patients, is the only FDA-approved Factor B inhibitor of the immune system
Sep 11, 2023 10:00 am ET
Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
Company Contact:Novartis Pharmaceuticals Corporation1-888-669-6682
Jun 08, 2023 07:00 am ET
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
SYDNEY, June 8, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting the University of Sydney on a molecularly-guided phase II clinical study to examine paxalisib in adult patients with recurrent/progressive isocitrate dehydrogenase (IDH) mutant grade 2 and 3 glioma (G2/3 gliomas).
Apr 25, 2023 12:44 pm ET
Thinking about trading options or stock in Spotify Technology, Novartis, Apple, UnitedHealth Group, or Honeywell?
NEW YORK, April 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPOT, NVS, AAPL, UNH, and HON.
Mar 06, 2023 07:00 am ET
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Novartis AG (NYSE: NVS) has exercised its options to license novel capsids generated from...
Dec 09, 2022 07:34 am ET
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it has entered into an...
Nov 21, 2022 08:31 am ET
Thinking about trading options or stock in AstraZeneca, Jacobs Solutions, J M Smucker, Tesla, or Novartis?
NEW YORK, Nov. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AZN, J, SJM, TSLA, and NVS.
Nov 09, 2022 08:35 am ET
Thinking about trading options or stock in Trade Desk, Meta, Novartis, Twitter, or Costco?
NEW YORK, Nov. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTD, META, NVS, TWTR, and COST.
Jul 20, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Novartis, Ebix, Intuit, and Argo and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Novartis AG (NYSE: NVS), Ebix, Inc. (NASDAQ: EBIX), Intuit, Inc. (NASDAQ: INTU), and Argo Group International Holdings, Ltd....
Jul 15, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Digital World, Generac, Novartis, and Cognyte and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Digital World Acquisition Corp. (NASDAQ: DWAC), Generac Holdings, Inc. (NYSE: GNRC), Novartis AG (NYSE: NVS), and Cognyte...
Jul 15, 2022 10:18 am ET
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE:
Jul 14, 2022 07:22 pm ET
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE:
Jul 13, 2022 09:06 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS
NEW YORK, July 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 10, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating the WWE, Digital World, Generac, and Novartis and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against World Wrestling Entertainment, Inc. (NYSE: WWE), Digital World Acquisition Corp. (NASDAQ: DWAC), Generac Holdings, Inc....
Jul 04, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Novartis, Unity Software, Gap, and Cassava and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Novartis AG (NYSE: NVS), Unity Software, Inc. (NYSE: U), Gap, Inc. (NYSE: GPS), and Cassava Sciences, Inc. (NASDAQ: SAVA)....
Jun 24, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Novartis, Medallion, RBB, and Agrify and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Novartis AG (NYSE: NVS), Medallion Financial Corp. (NASDAQ: MFIN), RBB Bancorp (NASDAQ: RBB), and Agrify Corporation...
Jun 23, 2022 05:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS
Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jun 22, 2022 07:00 am ET
Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing
Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, announced today the closing of a $119 million financing round led by Enavate Sciences,...
Jun 13, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Carvana, Enochian, Novartis, and Corcept and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE: CVNA), Enochian Biosciences, Inc. (NASDAQ: ENOB), Novartis AG (NYSE: NVS), and Corcept Therapeutics, Inc....
Jun 13, 2022 07:56 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS
Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jun 08, 2022 09:20 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS
NEW YORK, June 8, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 08, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Carvana, Enochian, Novartis, and Corcept and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE: CVNA), Enochian Biosciences, Inc. (NASDAQ: ENOB), Novartis AG (NYSE: NVS), and Corcept Therapeutics, Inc....
Jun 03, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Enochian, Novartis, Teladoc, and Tupperware and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Enochian Biosciences, Inc. (NASDAQ: ENOB), Novartis AG (NYSE: NVS), Teladoc Health, Inc. (NYSE: TDOC), and Tupperware Brands...
Jun 02, 2022 09:33 pm ET
NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) on behalf of Novartis stockholders. Our investigation concerns whether Novartis has violated the federal securities laws and/or engaged in other unlawful business practices.
Jun 01, 2022 09:00 pm ET
NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) on behalf of Novartis stockholders. Our investigation concerns whether Novartis has violated the federal securities laws and/or engaged in other unlawful business practices.
Jun 01, 2022 04:45 pm ET
Novartis AG, Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Novartis investors that...
Jun 01, 2022 12:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Novartis AG (NVS) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE:
May 31, 2022 06:00 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Novartis AG (NVS) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors concerning the Company’s possible violations of federal securities laws.
May 31, 2022 04:36 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Novartis AG (NVS) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Novartis AG (“Novartis” or the “Company”) (NYSE:
Mar 08, 2022 06:16 am ET
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today reported fourth quarter and full year 2021 financial and operating results....
Jan 26, 2022 08:00 am ET
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership...
Jan 10, 2022 10:30 am ET
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024
VANCOUVER, BC, Jan. 10, 2022 /PRNewswire/ -- USA News Group - Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed as leukemia, lymphoma and myeloma. According to analysts at Markets and Markets, the leukemia therapeutics market is projected to reach US$17.1 billion by 2024, growing at a CAGR of 6.8%. Along the way, there have been several positive developments in the fight against blood cancers including more recent updates from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), AbbVie Inc. (NYSE:ABBV), Novartis AG (NYSE:NVS), Thermo Fisher Scientific Inc.
Dec 10, 2021 07:02 am ET
Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
EAST HANOVER, N.J., Dec. 10, 2021 /PRNewswire/ -- Novartis today announced new Piqray® (alpelisib) data indicating benefit across a broad range of patient and disease characteristics as seen in analyses from all three cohorts of BYLieve. BYLieve is an ongoing Phase II, open-label, 3-cohort non-comparative study evaluating Piqray with endocrine therapy including men and pre- and postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (mBC) who have progressed on or after prior therapies, including
Sep 19, 2021 07:35 am ET
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
EAST HANOVER, N.J., Sept. 19, 2021 /PRNewswire/ -- Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combination with letrozole compared to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with no prior systemic treatment for advanced disease. These data will be presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) Cong
Aug 02, 2021 09:30 am ET
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
CARLSBAD, Calif., Aug. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for exclusive worldwide development and commercialization, continues to advance in the clinic as the potential first-in-class treatment for lipoprotein(a) or Lp(a)-driven cardiovascular disease. The Novartis pivotal Phase 3 cardiovascular outcomes study of pelacarsen, Lp(a) HORIZON (NCT04023552), has reached 50% enrollment with a target goal of 7,680 trial participants.
Jun 30, 2020 11:00 am ET
NVS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG and Encourages Investors to Contact the Firm
NEW YORK, June 30, 2020 /PRNewswire/ --Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novartis AG ("Novartis" or "the Company") (NYSE: NVS). Investors who purchased Novartis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/nvs.
Jun 26, 2020 07:32 pm ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that the board of directors of Novartis may have breached its fiduciary duties to shareholders.
Mar 26, 2020 01:16 pm ET
ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business information to the investing public.
Mar 10, 2020 01:00 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE:
Mar 09, 2020 10:38 am ET
ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...
Dec 27, 2019 10:53 am ET
ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...
Nov 25, 2019 04:55 pm ET
ROSEN, A GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business information to the investing public.
Nov 25, 2019 12:09 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of The Medicines Company to Novartis AG is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased The Medicines Company (the “Company”) (NASDAQ: MDCO) stock prior to November 24, 2019. You are hereby notified that Levi & Korsinsky, LLP...
Nov 09, 2019 08:34 pm ET
ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...
Oct 09, 2019 10:05 am ET
NVS LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...
Sep 30, 2019 06:52 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Novartis AG Investors of Important Deadline in Securities Class Action First Filed by the Firm – NVS
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novartis AG (NYSE: NVS) from December 3, 2018 to August 5, 2019, inclusive (the “Class Period”) of the important lead plaintiff deadline in the securities...
Sep 25, 2019 11:20 am ET
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities...
Sep 23, 2019 10:23 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG
Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) concerning possible violations of federal securities laws. On August 6, 2019, the United States Food and Drug...
Sep 18, 2019 11:40 am ET
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities...
Sep 13, 2019 10:15 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG
Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) concerning possible violations of federal securities laws. On August 6, 2019, the United States Food and Drug...
Sep 11, 2019 04:30 pm ET
Glancy Prongay & Murray LLP Continues its Investigation on Behalf of Novartis AG Investors (NVS)
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a...
Sep 11, 2019 01:44 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Continues its Investigation on Behalf of Novartis AG Investors (NVS)
Law Offices of Howard G. Smith continues its investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors concerning the Company and its officers’ possible violations of federal securities laws. On August 6, 2019, the...
Sep 11, 2019 09:28 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities...
Sep 10, 2019 06:45 pm ET
NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities Claims Against Novartis AG; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business information to the investing public.
Sep 07, 2019 10:00 am ET
ROSEN, A LEADING LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business information to the investing public.
Sep 05, 2019 05:00 pm ET
ROSEN, A TOP RANKED LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...
Sep 04, 2019 02:10 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG
Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) concerning possible violations of federal securities laws. On August 6, 2019, the United States Food and Drug...
Sep 04, 2019 11:30 am ET
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities...
Aug 29, 2019 11:52 am ET
EQUITY ALERT: Rosen Law Firm Continues To Investigate Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...
Aug 27, 2019 12:03 pm ET
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities...
Aug 21, 2019 11:50 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities...
Aug 20, 2019 04:00 pm ET
Glancy Prongay & Murray LLP Continues its Investigation on Behalf of Novartis AG Investors (NVS)
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE:
Aug 20, 2019 03:06 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE:
Aug 20, 2019 01:42 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Continues its Investigation on Behalf of Novartis AG Investors (NVS)
Law Offices of Howard G. Smith continues its investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors concerning the Company and its officers’ possible violations of federal securities laws.
Aug 19, 2019 06:09 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE:
Aug 19, 2019 03:58 pm ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG – NVS
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business information to the investing public.
Aug 07, 2019 09:30 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Novartis AG Investors (NVS)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE:
Aug 07, 2019 07:42 pm ET
Novartis (NVS) Alert: Johnson Fistel Launches Investigation into Novartis AG; Investors Encouraged to Contact Firm
SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Novartis AG ("Novartis") (NYSE: NVS) for violations of federal securities laws.
Aug 07, 2019 07:05 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Novartis AG Investors (NVS)
Law Offices of Howard G. Smith announces an investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors concerning the Company and its officers’ possible violations of federal securities laws.
Aug 06, 2019 06:36 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG
Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) concerning possible violations of federal securities laws. On August 6, 2019, the United States Food and Drug...
May 24, 2019 01:09 pm ET
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
BASEL, Switzerland, May 24, 2019 /PRNewswire/ -- AveXis, a Novartis company, today announced the US Food and Drug Administration (FDA) has approved Zolgensma® (onasemnogene abeparvovac-xioi) for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. Zolgensma is designed to address the genetic root cause of SMA by providing a functional copy of the human SMN gene to halt disease progression through sustained SMN protein expression with a single, one-time intravenous (IV) infusion. Z
Feb 25, 2019 07:55 am ET
Detailed Research: Economic Perspectives on Novartis AG, Proteostasis Therapeutics, Williams-Sonoma, Magna International, YRC Worldwide, and Delek Logistics Partners — What Drives Growth in Today's Co
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Novartis AG (NYSE:NVS), Proteostasis Therapeutics, Inc. (NASDAQ:PTI),...
Nov 19, 2018 06:46 pm ET
Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder
reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)Adding reSET to outpatient therapy significantly improved abstinence in substances of abuse and treatment retention compared to standard of...
Nov 02, 2018 05:27 pm ET
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
EAST HANOVER, N.J., Nov. 2, 2018 /PRNewswire/ -- Novartis will present new research that may transform the way serious blood diseases and a certain type of breast cancer are treated at the upcoming 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, December 1-4 and the 41st Annual San Antonio Breast Cancer Symposium (SABCS), December 4-8. Nearly 150 abstracts will be presented across both congresses, underscoring the strength of the Novartis pipeline and portfolio in hematology and oncology.
Oct 26, 2018 08:55 am ET
Market Trends Toward New Normal in Chesapeake Utilities, Schlumberger, American Eagle Outfitters, Spark Energy, Maximus, and Novartis AG — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Chesapeake Utilities Corporation (NYSE:CPK), Schlumberger Limited...
Oct 09, 2018 04:53 pm ET
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
EAST HANOVER, N.J., Oct. 9, 2018 /PRNewswire/ -- Results from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumab, a humanized anti-P-selectin monoclonal antibody being investigated for the treatment of sickle cell disease (SCD), have been published in the American Journal of Hematology. The analysis showed that more patients treated with crizanlizumab did not experience a vaso-occlusive crisis (VOC) vs those treated with placebo (35.8% vs 16.9%), specifically patients with a history of 2-10 VOCs in the previous year.
Sep 28, 2018 08:00 am ET
Report: Developing Opportunities within AstraZeneca, Manulife Financial, Infosys, Novartis AG, Black Hills, and Shell Midstream Partners — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AstraZeneca PLC (NYSE:AZN), Manulife Financial Corp (NYSE:MFC), Infosys...
Jul 12, 2018 07:15 am ET
Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community
- Galaxies of Hope offers a unique digital experience that engages users through the art of visual storytelling to connect with others to understand NET cancer
Jun 15, 2018 07:00 am ET
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
EAST HANOVER, N.J., June 15, 2018 /PRNewswire/ -- Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results of a Novartis survey, called I-WISh, presented today at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden (Abstract #PF654).
Jun 08, 2018 08:30 am ET
Detailed Research: Economic Perspectives on Koninklijke Philips N.V, Corporacion America Airports S.A, BHP Billiton, HSBC Holdings plc, Weatherford International, and Novartis AG — What Drives Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Koninklijke Philips N.V. (NYSE:PHG), Corporacion America Airports S.A....
May 09, 2018 08:00 am ET
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)
CUPERTINO, Calif., May 9, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has entered into an amendment (the "Amendment") to the development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), regarding POSIMIR® (SABER®-bupivacaine) in the United States.
Apr 19, 2018 09:16 am ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXS
NEW YORK, April 19, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating AveXis, Inc. ("AveXis" or the "Company") (NasdaqGS: AVXS) relating to the sale of the Company to affiliates of Novartis AG (NYSE: NVS). As a result of the merger AveXis shareholders are only anticipated to receive $218 in cash in exchange for each share of AveXis.
Apr 09, 2018 09:31 am ET
Thinking about buying stock in Acadia Pharmaceuticals, Deutsche Bank, General Motors, Novartis, or Spirit Airlines?
CHICAGO, April 9, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, DB, GM, NVS, and SAVE.
Mar 27, 2018 08:30 am ET
Investor Expectations to Drive Momentum within Ambev S.A, AC Immune SA, Comp En De Mn Cemig ADS, GSV Capital, Novartis AG, and New York — Discovering Underlying Factors of Influence
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ambev S.A. (NYSE:ABEV), AC Immune SA...
Feb 01, 2018 04:05 pm ET
Advanced Accelerator Applications Announces Completion of Subsequent Offering Period for Novartis Tender Offer
SAINT-GENIS-POUILLY, France, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), a Novartis company and a leader in nuclear medicine theragnostics, today announced that a subsidiary of Novartis AG (NYSE:NVS) (“Novartis”), Novartis...
Dec 11, 2017 10:03 am ET
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
EAST HANOVER, N.J., Dec. 11, 2017 /PRNewswire/ -- Results from a post hoc subgroup analysis of the Phase II SUSTAIN study show that crizanlizumab, an investigational humanized anti-P-selectin monoclonal antibody, delayed the time to first sickle cell pain crisis (SCPC) in patients vs. placebo in key subgroups of adult patients with sickle cell disease1. Findings were featured during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting (Abstract #613; Monday, December 11, 10:30 AM ET).
Dec 07, 2017 07:00 am ET
Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer
SAINT-GENIS-POUILLY, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that a direct and indirect subsidiary of Novartis AG (NYSE:NVS), Novartis Groupe France...
Dec 05, 2017 04:00 pm ET
Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis
SAINT-GENIS-POUILLY, France, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that its Board of Directors, following the completion of the information and consultation...
Nov 11, 2017 08:01 am ET
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
Poor patients in Punjab will have access to high-quality medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will make medicines available free of charge through public sector hospitals from early 2018 onward Pakistan is among the countries most affected by chronic diseases; more than half of its population lives in the Punjab province Basel, 11 November 2017 - Today, the provincial government of Punjab in Pakistan signed a Memorandum of Understanding with Novartis to roll out Novartis Access. Poor patien...
Nov 10, 2017 05:52 pm ET
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept Significantly fewer brolucizumab patients showed signs of disease activity as well as retinal fluid (IRF and/or SRF)-key markers used by physicians to determine injection frequency in clinical practice Brolucizumab delivered superior reductions in retinal thickness (CST) due to fluid accumulation versus aflibercept Overall ocular and non-ocular adverse event rates for ...
Nov 07, 2017 01:16 am ET
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced mobility and irreversible joint damage[2] FUTURE 5 is the largest randomized controlled trial of a biologic conducted to date in PsA, with nearly 1,000 patients studied[1] Basel, November 7, 2017 - Novartis announced today results from the FUTURE 5 study showing Cosentyx® (secukinumab) reduced the signs and symptoms of psoriatic arthritis (PsA) while significantly inhibiting the progression of joint...
Nov 02, 2017 04:31 pm ET
Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD) Clinical trial is part of the Generation Program, which includes cognitively healthy people at genetic risk of developing AD Generation Study 2 aims to include a broader high-risk population, as compared to the ongoing Generation Study 1 44 million people globally are estimated to have AD or a related dementia, with one new case diagnosed every three seconds[1],[2] Basel, November 2, 2017 - Novartis, Amgen and t...
Nov 01, 2017 10:14 am ET
Nov 01, 2017 09:06 am ET
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Primary results of pivotal KymriahTM Phase II JULIET study in relapsed/refractory DLBCL Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickle cell pain crisis Outcomes from matched analysis of Molecular Recurrence-free Survival from EURO-SKI and ENESTfreedom trials following Tasigna® vs. imatinib in patients with CML-CP eligible for Treatment-free Remission (TFR) Additional data on Rydapt®, Revolade®/Promacta®, Exjade®/Jadenu® and Jakavi® underscore breadth of Novartis Oncology hematology portfolio Basel, November 1, 2017 - No...
Oct 02, 2017 01:16 am ET
Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
Clareon® intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations Congress program highlights Alcon's 70-year legacy of innovation including 100 million AcrySof® IOL implants New analyses show efficacy and safety of CyPass® Micro-Stent in patients with glaucoma Basel, October 2, 2017 - Alcon, the global leader in eye care and a division of Novartis, will introduce Clareon®, the intraocular lens (IOL) with the most advanced optic material available in an automated, disposable, pre-loaded delivery system, at the X...
Sep 22, 2017 01:16 am ET
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model GIPAP was introduced 15 years ago and has provided approximately 75,000 patients access to free, cancer treatment The Max Foundation to lead program for patients and oversee supply chain management; Novartis to contribute funding and product donation Basel, September 22, 2017 - Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chr...
Sep 12, 2017 01:17 am ET
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis[1] Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our biosimilar rituximab matches the reference medicine in terms of safety, efficacy and quality The global leader in biosimilars, Sandoz has five biosimilars approved worldwide including biosimilar rituximab, which was approved in Europe* in June 2017[2] Holzkirchen, September 12, 2017 - Sandoz, a Novartis Division, and the pioneer and global leader in biosimilars, announced today that the U...
Sep 10, 2017 06:06 pm ET
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified subgroups, including patients with stage III A, B and C melanoma[1] Study demonstrated clinically meaningful improvements in secondary endpoints, including overall survival (OS), distant metastasis-free survival (DMFS) and freedom from relapse (FFR) [1]First adjuvant targeted therapy combination to demonstrate a clinical benefit in patients with a BRAF V600 mutation[1] Results from COMBI-AD pres...
Sep 07, 2017 04:31 pm ET
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need Dedicated cardiovascular safety study reaffirmed placebo-like tolerability of erenumab as seen consistently across the comprehensive clinical program Erenumab is the first and only fully human monoclonal antibody of its kind, uniquely designed to specifically block the CGRP receptor, which plays a critical role in activation of migraine The digital press release with multimedia content can be accessed h...
Sep 04, 2017 01:01 am ET
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position. The Board of Directors has appointed Vasant (Vas) Narasimhan, M.D., Global Head of Drug Development and Chief Medical Officer, as CEO of Novartis, effective February 1, 2018. Dr. Narasimhan is a member of the Executive Committee and joined Novartis in 2005....
Aug 27, 2017 05:01 am ET
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard of care including lipid-lowering therapy Effect driven by 24% relative reduction in risk of heart attack; a non-significant 10% reduction in risk of cardiovascular death was observed Sub-group of study participants whose inflammation was reduced below the median hsCRP saw a 27% relative risk reduction on primary MACE end-point Additionally, a review of blinded, pre-pla...
Aug 27, 2017 05:01 am ET
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a long-established hypothesis from pre-clinical models that inhibition of IL-1ß impacts cancer incidence and mortality CANTOS cardiovascular study which met primary endpoint as published in The New England Journal of Medicine, validating anti-inflammatory agent impacts cardiovascular risk reduction Novartis plans to discuss lung cancer hypothesis wi...
Aug 24, 2017 01:20 am ET
Novartis appoints Bertrand Bodson as Chief Digital Officer
New leader to drive the digital transformation Novartis has embarked upon Basel, August 24, 2017 - Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, reporting to Joseph Jimenez, CEO of Novartis. ...
Aug 24, 2017 01:12 am ET
Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Approval is based on pivotal MONALEESA-2 trial, which showed Kisqali plus letrozole reduced risk of disease progression or death by 43% versus letrozole alone[1] Kisqali plus letrozole demonstrated a median progression-free survival (PFS) of 25.3 months versus 16.0 months of patients who received letrozole alone[1] Kisqali plus letrozole demonstrated rapid clinical improvement in patients with measurable disease, with 76% seeing a reduction in tumor size after only eight weeks versus 67% with letrozole alone[2] Up to one-third of patients with early-stage breast cancer will subsequ...
Aug 21, 2017 01:17 am ET
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission KAF156 is first compound from the imidazolopiperazines, a novel class of antimalarials, to enter phase IIb combination studies Clinical trial has started early August in adults with malaria and is planned to expand to adolescents and children in a total of nine countries in Africa and Asia Basel, August 21, 2017 - Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-gene...
Jul 25, 2017 01:16 am ET
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana In developed countries, the survival rate for childhood cancer is 80%, while in developing countries it can be as low as 10% Sandoz is committed to working with key stakeholders to pioneer novel ways of expanding access to healthcare The digital press release with multimedia content can be accessed here: ...
Jul 14, 2017 01:23 pm ET
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis[1] Data planned to be presented at a key medical congress in the second half of 2017. 5 year Phase III data is a recognized milestone for assessing long-term efficacy and safety of innovative treatments Recently announced EU approval for Cosentyx label update underlined long-term superiority versus Stelara®* in psoriasis, and efficacy in moderate-to-severe scalp psoriasis[2],[3] Basel, July 14, 2017 - Novartis, a global lead...
Jul 12, 2017 05:21 pm ET
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become first CAR-T cell therapy available Positive ODAC recommendation is latest milestone for CTL019 program that started through collaboration with the University of Pennsylvania Basel, July 12, 2017 - Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommen...
Jun 19, 2017 08:00 am ET
DURECT's Collaboration with Sandoz Clears HSR Review and is Effective
CUPERTINO, Calif., June 19, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the previously disclosed development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), to develop and market in the United States DURECT's POSIMIR® (SABER®-Bupivacaine), an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery, has cleared review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and has become effective.
Jun 15, 2017 02:01 pm ET
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®
FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus® Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicine Sandoz looks forward to working with FDA to drive access to this treatment option Holzkirchen, June 15, 2017- Sandoz today announced that the US Food and Drug Administration (FDA) has accepted its Abbreviated New Drug Application for fluticasone propionate / salmeterol combination product, a substitutable generic version of Advair Diskus®[1]....
Jun 15, 2017 01:19 am ET
Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
Cosentyx® is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] Additional data show rapid and sustained pain relief with Cosentyx as early as Week 3 which is sustained out to 2 years in PsA patients[3] Patient recruitment underway for the new EXCEED head-to-head clinical trial to show superiority of Cosentyx versus Humira®* in PsA[4] The digital press release with multimedia content can be accessed here:...
Jun 08, 2017 04:30 pm ET
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month AMG 334 (erenumab) significantly reduced monthly migraine days in patients with the highest need, suffering from chronic migraine with acute medication overuse Migraine patients urgently need new treatment options, as currently available preventive therapies are often discontinued due to side effects or lack of effectiveness The digital press release with multimedia content can be accessed here: ...
Jun 05, 2017 04:05 pm ET
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
Phase I/II study to evaluate Mekinist® (trametinib) in combination with Opdivo® (nivolumab) and Opdivo + Yervoy® (ipilimumab) Collaboration expands upon existing clinical investigation of Opdivo combination with Novartis investigational and marketed therapies Basel, June 5, 2017 - Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment option for me...
Jun 04, 2017 09:01 am ET
Novartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
Study is longest follow-up to date of a BRAF and MEK inhibitor combination therapy in patients with BRAF V600-mutant metastatic melanoma[1]Study shows stable overall survival and progression-free survival lasting more than five years with consistent tolerability[1]Initial data from separate Phase II trial of BRAF and MEK inhibitors showed positive results in BRAF V600-mutant melanoma patients with metastatic brain metastases[2] Basel, June 4, 2017 - Novartis today announced results from a Phase II study showing a durable survival benefit for some patients with BRAF V600 mutation-positive...
May 31, 2017 01:10 am ET
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®** Comprehensive data packages demonstrate each biosimilar matches its respective reference medicine in terms of quality, efficacy and safety These regulatory submissions follow soon after two positive CHMP opinions*** for Sandoz biosimilars etanercept and rituximab further reinforcing Sandoz immunology pipeline and the broader Novartis immunology portfolio Holzkirchen, 31 May, 2017 - Sandoz, a Novartis division,...
May 31, 2017 01:01 am ET
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become stronger and more integrated through centralized manufacturing, development and business servicesPoised for next growth phase, anticipated to begin in 2018 Boston, May 31, 2017 - Today Novartis holds its fourth annual Meet Novartis Management event at its research headquarters in Cambridge, MA, giving investors and analysts the opportunity to meet with 30 executives across its three divisions, R&...
May 30, 2017 05:01 pm ET
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months.CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the University of PennsylvaniaNovartis is committed to advancing a portfolio of next-generation CAR-T cell therapies Basel, May 30, 2017 - Novartis announced findings from a pilot study (NCT02640209) of CTL119 in combination with ibrutinib* in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who had been taking ibrutinib for at least six months and who were not in complete ...
May 08, 2017 08:00 am ET
DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States
CUPERTINO, Calif., May 8, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), to develop and market in the United States DURECT's POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.
Apr 24, 2017 04:30 pm ET
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the US and Canada
Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the US; Novartis to gain exclusive rights in Canada Novartis retains commercial rights in rest of world; Amgen retains commercial rights in Japan Companies to combine capabilities and leverage Novartis strong and established neuroscience presence in the US and across the globe to maximize launch of AMG 334 (erenumab) Basel, April 24, 2017 - Novartis today announced an expanded commercialization agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine. This agreement builds on ...
Apr 24, 2017 01:15 am ET
Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS
Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the range expected for people without MS Approximately 60% of patients achieved NEDA-3 (no relapses, no MRI lesions and no disability progression combined) and 38% achieved NEDA-4 (NEDA-3 plus no brain shrinkage), further supporting findings from clinical trials First real-world multicenter study showing that monitoring brain shrinkage using routine imaging methods is reliable and could be adopted...
Apr 21, 2017 01:43 pm ET
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*
Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Biosimilar rituximab also recommended to treat blood cancers Comprehensive data packages, confirming Sandoz biosimilars rituximab and etanercept match their respective reference medicines, were the basis for CHMP decisions Subject to EC** approval, Sandoz market leadership position extended as the only company to have five approved biosimilars in Europe[1] Holzkirchen, April 21, 2017 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, annou...
Apr 19, 2017 05:01 pm ET
NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
NIH study found 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard immunosuppressive therapy[1] The historical complete response rate was 10% for untreated patients with SAA on immunosuppressive therapy alone[1] Findings were published in The New England Journal of Medicine (NEJM) and will be submitted to regulatory bodies for treatment-naïve SAA Basel, April 19, 2017 - Novartis today announced the publication of a study conducted by the National Heart, Lung, an...
Apr 18, 2017 01:16 am ET
Novartis expands development programs for NASH through clinical collaboration with Allergan
Phase IIb clinical trial to evaluate a combination of a Novartis FXR agonist and Allergan's cenicriviroc for NASH, a progressive form of non-alcoholic fatty liver disease There are currently no approved treatments for NASH, which is a major cause of liver disease worldwide and the leading cause of liver transplants for people under 50 in the US[1] Novartis has a rapidly growing development portfolio in NASH, investigating single and combination therapies across all stages of the disease Basel, April 18, 2017 - Novartis announced today that it has entered into a clinical trial agreeme...
Apr 18, 2017 01:11 am ET
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) R/r DLBCL, an aggressive cancer with limited options, is the second indication for CTL019 to receive Breakthrough Therapy designation Advances in CTL019 result from collaboration with the University of Pennsylvania; regulatory submissions for r/r DLBCL are expected to be filed by the end of the year Basel, April 18, 2017 - Novartis announced today that the US Food and Drug Administration (FDA) has granted Br...
Apr 03, 2017 01:15 am ET
Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)
New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC Approval based on data showing more than 60% overall response rate in both previously treated and untreated patients[1] Approximately 1-3% of patients with lung cancer are diagnosed annually with BRAF V600-positive NSCLC worldwide Basel, April 3, 2017 - Novartis today announced the European Commission has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic non-...
Mar 29, 2017 04:00 pm ET
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cellsNovartis made an early commitment to the emerging field of CAR-T investigational therapies through collaboration with the University of Pennsylvania including CTL019Novartis plans to submit an application for market authorization with the European Medicines Agency (EMA) later this year Basel, March 29, 2017 - Novartis announced today that the US Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA)...
Mar 23, 2017 02:15 am ET
Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
The unique optical design of the ACTIVEFOCUS(TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses The lens is based on the proven AcrySof® IQ toric IOL platform that delivers unrivaled rotational stability[1] This extends the market-leading AcrySof® IQ platform to a broader population of the nearly 2 million cataract patients with treatable levels of astigmatism who undergo cataract surgery each year[2] Basel, March 23, 2017 - Alcon, the global leader in eye care and a division of Novar...
Mar 22, 2017 02:15 am ET
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure Novartis remains committed to improving and extending the lives of patients with cardiovascular disease and will continue to invest in ways to improve their outcomes Basel, March 22, 2017 - Novartis today announced results from the global Phase III RELAX-AHF-2 study investigating the efficacy, safety and tolerability of RLX030 (serelaxin) in patients with acute heart failure (AHF). ...
Mar 18, 2017 09:46 am ET
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced ejection fraction (HFrEF) patients who also had diabetes New use of insulin was also reduced by 29% among patients taking Entresto compared to enalapril-treated patients[1] Up to 40% of HFrEF patients have diabetes, which is associated with worse cardiovascular outcomes[2] New analysis presented today at the American College of Cardiology (ACC) Annual Scientific Session and published in The...
Mar 13, 2017 03:09 pm ET
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
Approved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] At this interim analysis, Kisqali plus letrozole reduced risk of disease progression or death by 44% over letrozole alone, and demonstrated tumor burden reduction with a 53% overall response rate[1] Kisqali plus letrozole showed treatment benefit across all patient subgroups regardless of disease burden or tumor location[1] At a subsequent analysis with additional follow-up and progression events, a...
Mar 13, 2017 02:15 am ET
Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines. Winning ideas proposed novel ways to use mobile technologies to connect patients with caregivers and essential medicines Sandoz invited young people worldwide to "reimagine access to healthcare" - arguably the largest unmet medical need London, March 13, 2017 - Sandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare Access Challenge (Sandoz HACk). The winners, chosen by a panel ...
Feb 28, 2017 07:44 am ET
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
Shareholders approve 20th consecutive dividend increase to CHF 2.75 (+2%) per share for 2016; representing a 3.5% yield and approximately 69% payout of free cash flow Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well as all other members who have stood for re-election; Frans van Houten elected as new member of the Board Shareholders approve all other proposals of the Board of Directors, including future Board and Executive Committee compensation Basel, February 28, 2017 - Novartis shareholders today agreed to the Board of Directors' r...
Feb 08, 2017 06:00 am ET
Propeller Health Enters into Collaboration to Connect Breezhaler™ Devices to the Propeller Platform
MADISON, Wis., Feb. 8, 2017 /PRNewswire/ -- Propeller Health, the leading digital health solution for respiratory medicine, and Novartis Pharma AG (NYSE: NVS) today announced a collaboration to develop a custom add-on sensor for the Breezhaler™ inhaler, a device used for the company's portfolio of COPD treatments (Ultibro™ Breezhaler™, Onbrez™ Breezhaler™ and Seebri™ Breezhaler™), connecting these medications to Propeller's digital health platform.
Jan 26, 2017 01:15 am ET
Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
Novartis Access-to-medicine programs reached approximately 52 million patients, including first-year deliveries through the innovative Novartis Access program Novartis improved position in key sustainability rankings, including recent Corporate Knights' "Global 100 Most Sustainable Corporations in the World" 2016 report highlights work towards the United Nations Sustainable Development Goals and shares trends and challenges within the healthcare industry Basel, January 26, 2017 - Novartis published its Corporate Responsibility (CR) Performance Report for the fourth consecutive y...
Jan 26, 2017 01:10 am ET
Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
Innovative AcrySof® IQ PanOptix® Toric intraocular lens (IOL) extends Alcon's trifocal PanOptix® IOL portfolio to a wider range of patients CE-marked in November 2016, this IOL offers excellent near-to-intermediate vision, and increased independence from glasses while addressing astigmatism More than 70 percent of patients worldwide undergoing cataract surgery have treatable levels of astigmatism[1] BASEL, Switzerland, January 26, 2017 - Alcon, the global leader in eye care and a division of Novartis, announces the launch of AcrySof® IQ PanOptix® Toric presbyopia- and astigmatism-...
Jan 06, 2017 01:15 am ET
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated levels of lipoprotein Lp(a) or ApoCIII, which is a potent regulator of triglyceridesInvestment in biomarker-based therapies bolsters Novartis' cardiovascular specialty pipeline and commitment to address unmet medical need of high-risk atherosclerosis/dyslipidemia patients Atherosclerosis, commonly called the "silent killer", is a major cause of death globally and no options exist today to effec...
Dec 20, 2016 01:15 am ET
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.
Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc. to add first-in-class disease modifying topical treatment for presbyopia patients to the Novartis ophthalmology pipeline in an area of high unmet medical need and high prevalence Presbyopia is an age-related loss of near distance vision affecting approximately 80% of people over the age of 45; characterized by a progressive inability to focus on objects nearby, making everyday activities such as reading challenging; current therapies only provide optical correction witho...
Dec 19, 2016 04:30 pm ET
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
Novartis to broaden liver portfolio to deliver best-in-class single and combination therapies for non-alcoholic steatohepatitis (NASH) with advanced fibrosis and cirrhosis through an option, collaboration and license agreement with Conatus There are currently no approved treatments for NASH patients in all stages of the disease, which is expected to be the leading cause of liver transplants in the US by 2020[1] Novartis has FXR agonists in clinical development for NASH, the most advanced of which is in a Phase 2 clinical trial and has been granted Fast Track designation from the US FDA ...
Dec 16, 2016 01:15 am ET
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
Acquisition to add a once-daily oral H4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline Investigational ZPL389 showed a clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score compared to placebo after eight weeks of treatment with a favorable safety profile Eczema is a chronic, inflammatory skin condition affecting millions of children and adults worldwide[1] with an unmet need for effective and safe oral treatments Basel, December 16, 2016 - Nov...
Dec 08, 2016 01:15 am ET
Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment
Ultibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the 2017 GOLD recommendations that dual bronchodilation should be the foundation treatment for the majority of symptomatic COPD patients Data from the pragmatic CRYSTAL study showcased for the first time at the 2016 British Thoracic Society Winter Meeting in London, UK Basel, December 8, 2016 - Novartis today announced positive results from the first large-scale study exploring the effects of directl...
Dec 05, 2016 01:30 pm ET
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®
ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients[1] The Tasigna TFR trials, including ENESTop, demonstrate our continued commitment to the CML community Basel, December 5, 2016 - Novartis today announced at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition new data from the Tasigna® (nilotinib) ENESTop Treatment-free Remission (TFR) study, which demonstrate that TFR rates are consistent among Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) patients who switched from ...
Dec 05, 2016 01:16 am ET
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product[1] Interim data in over 600 adults show potential of GP2013 as an alternative rituximab[1] Sandoz proposed biosimilar rituximab is the company's first monoclonal antibody candidate Holzkirchen, December 5, 2016 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial. The confirmatory safety and efficacy study shows GP2013 met its primary endpoint...
Dec 03, 2016 07:01 pm ET
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T cell trial, will be the basis of a Biologics Licensing Application (BLA) to the FDA in early 2017 Novartis pivotal data from ELIANA is supported by CTL019 US multicenter trial (ENSIGN) as well as earlier single site trial in r/r pediatric and young adult patients with B-cell ALL The University of Pennsylvania (Penn) will present findings evaluating overall response to CTL019 therapy among r/r ...
Dec 03, 2016 01:00 pm ET
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
SEG101 reduced annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo in patients with or without hydroxyurea therapy SEG101 is a potential new disease-modifying, preventive treatment option for patients with SCPC; first in nearly 20 years Data being highlighted in ASH 2016 media briefing, presented at Plenary Scientific Session and published simultaneously in The New England Journal of Medicine Basel, December 3, 2016 - Results from the Phase II SUSTAIN study show that SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the med...
Nov 29, 2016 01:16 am ET
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than 100,000 monthly treatments to Kenya, Ethiopia and Lebanon* First-year learnings underline broader systemic issues in roll-out countries The digital press release with multimedia content can be accessed here:...
Nov 16, 2016 04:30 pm ET
Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study
STRIVE, the first six-month placebo-controlled study of AMG 334 (erenumab) in migraine, met the primary endpoint, showing a statistically significant reduction in monthly migraine days versus placebo Episodic migraine, characterized by up to 14 migraine days each month, can lead to individuals missing days from work, school and social activities AMG 334 is being co-developed by Novartis and Amgen; companies to pursue discussions with regulatory agencies for potential filings in respective territories Basel, November 16, 2016 - Novartis today announced positive topline results from ...
Nov 16, 2016 01:15 am ET
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
First results from global registrational trial of CAR T therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia Sub-group analyses from pivotal MONALEESA-2 trial of LEE011 (ribociclib) plus letrozole in women with HR+/HER2- advanced breast cancerPost-hoc analysis of Tasigna® (nilotinib) treatment-free remission rates in patients who switched from imatinib due to intolerance, resistance or physician preference Basel, November 16, 2016 - Novartis will present data demonstrating the latest advancements from its oncology research program at the 58th American Society o...
Nov 15, 2016 01:00 pm ET
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril[1] These findings are consistent with the benefit Entresto showed in reducing the risk of a first event, which was the primary endpoint of the PARADIGM-HF trial[2] Additional new analyses show that compared to enalapril, Entresto was associated with more diuretic dose reductions, lowered risk of severe hyperkalemia in patients taking an MRA, and reduced risk among HFrEF patients with the most severe...
Sep 23, 2016 02:09 pm ET
Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
EAST HANOVER, N.J., Sept. 23, 2016 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris® (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.